Search - tctmd.com

Displaying 221 - 240 of 665

Sort: Relevancy | Date

Presentation TCT 2017

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Presenter: Petr Kala, Jochen Wöhrle, Martin Hudec

October 30, 2017

Presentation TCT 2017

First-in-Human Study of a Novel Transradial Device for Intra-aortic Embolic Deflection During TAVR Implantation

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Darren Mylotte

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Perfusion-balloon Valvuloplasty Facilitating TAVR Without Rapid Pacing: The TRUE-FLOW Study

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Felix Woitek

October 30, 2017

Presentation TCT 2017

Human Cell Derived Off-The-Shelf Tissue Engineered Heart Valves for Next Generation TAVR: A Proof-of-Concept Study in Adult Sheep

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Valentina Lintas

October 30, 2017

Presentation TCT 2017

First-in-Man Experience With a Large Bore (?14 FR) Bio-Resorbable Vascular Closure Device

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Ronald Caputo

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Presentation TCT 2017

Transcatheter Aortic Valve Replacement With the HLT Meridian® Valve: Initial Clinical Experience

Presenter: Nicolo Piazza, Josep Rodés-Cabau

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey V: Addressing Complications and Follow-up

Presenter: Martina Kelly Speight, Amy E. Simone

October 30, 2017

Presentation TCT 2017

Effect of a New Enhanced Fluoroscopy Technology (Valve ASSIST2) on Contrast and Radiation Use in Patients Undergoing TAVR

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Ali Shafiq

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Craig R. Smith

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey IV: The Hospital Experience

Presenter: Martina Kelly Speight, Sandra Lauck

October 30, 2017

Presentation TCT 2017

Featured Lecture: TAVR Innovation: Unresolved Clinical Issues and Opportunities For Further Technology Optimization

Presenter: Nicolo Piazza, Josep Rodés-Cabau

October 30, 2017

Presentation TCT 2017

Case #4: TAVR for Pure Native Aortic Regurgitation - A Horrifying Ride

Presenter: Jun-Jack Cheng, Wasan Udayachalerm, Wei-Hsian Yin

October 30, 2017

Presentation TCT 2017

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Presenter: A. Pieter Kappetein

October 30, 2017

Presentation TCT 2017

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

Presenter: Susheel K. Kodali

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey III: Behind the Scenes

Presenter: Martina Kelly Speight, Sarah Clarke

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey II: Imaging Assessment

Presenter: Martina Kelly Speight, João L Cavalcante

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey I: Initial Evaluation

Presenter: Martina Kelly Speight, Patricia Keegan

October 30, 2017

Presentation TCT 2017

Case Presentation 5: TAVR

Presenter: Sergey A. Abugov, Juan F. Granada, Alexey Protopopov

October 29, 2017

Advertisement

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

First-in-Human Study of a Novel Transradial Device for Intra-aortic Embolic Deflection During TAVR Implantation

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Perfusion-balloon Valvuloplasty Facilitating TAVR Without Rapid Pacing: The TRUE-FLOW Study

Human Cell Derived Off-The-Shelf Tissue Engineered Heart Valves for Next Generation TAVR: A Proof-of-Concept Study in Adult Sheep

First-in-Man Experience With a Large Bore (?14 FR) Bio-Resorbable Vascular Closure Device

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Transcatheter Aortic Valve Replacement With the HLT Meridian® Valve: Initial Clinical Experience

TAVR Patient Journey V: Addressing Complications and Follow-up

Effect of a New Enhanced Fluoroscopy Technology (Valve ASSIST2) on Contrast and Radiation Use in Patients Undergoing TAVR

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

TAVR Patient Journey IV: The Hospital Experience

Featured Lecture: TAVR Innovation: Unresolved Clinical Issues and Opportunities For Further Technology Optimization

Case #4: TAVR for Pure Native Aortic Regurgitation - A Horrifying Ride

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

TAVR Patient Journey III: Behind the Scenes

TAVR Patient Journey II: Imaging Assessment

TAVR Patient Journey I: Initial Evaluation

Case Presentation 5: TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content